首页 > 最新文献

Indian journal of cancer最新文献

英文 中文
Prognostic Value of Systemic Inflammatory Markers in Elderly Patients with Tumor-associated Venous Thromboembolism. 全身炎症标志物在老年肿瘤相关性静脉血栓栓塞患者中的预后价值。
IF 0.9 4区 医学 Q4 ONCOLOGY Pub Date : 2024-12-19 DOI: 10.4103/ijc.ijc_318_23
Na Guo, Xinxin Yan, Zhong Yi, Shuihua Yu, Helu Xiu, Yunlei Gao, Songwei Ru, Zuojuan Gong
<p><strong>Background: </strong>Elderly tumor patients are more prone to venous thrombotic events than nontumor patients. To investigate the relationship between systemic inflammatory markers and overall survival (OS) in elderly patients with tumorassociated venous thromboembolism (TAVTE). And to evaluate the prognostic value of combined lymphocyte platelettolymphocyte ratio (PLR) with neoplasm metastasis in elderly patients.</p><p><strong>Methods: </strong>A prospective study was conducted. A total of 172 elderly patients with TAVTE admitted to the hospital from January 2017 to December 2019 were included in the study, which were followed up for 2 years. Clinical and laboratory data were collected. All-cause mortality within after discharge were followed up. The optimal cutoff values of neutrophiltolymphocyte ratio (NLR), PLR, systemic immuneinflammation index (SII), and monocyte to highdensity lipoprotein ratio (MHR) for predicting efficacy and prognosis were determined according to receiver operating characteristic (ROC) curve and the areas under the ROC curve (AUC). Kaplan-meier curves were used to analyze the survival time. Univariate and multivariate COX logistic regression analyses were used to analyze the independent predictors of OS in elderly patients with TAVTE.</p><p><strong>Results: </strong>The cut-off values for NLR, PLR, SII, and MHR were 3.375, 274.63, 399.73 and 0.58, respectively. And the area under the curve (AUC) was 0.639(95%CI: 0.556-0.721), 0.628(95%CI:0.544-0.712), 0.595(95%CI:0.510-0.680) and 0.596(95%CI: 0.510-0.683). Survival analysis showed that OS was longer in the NLR≤3.375 group (181.07 weeks, 95% CI: 150.11 ~ 212.03) than in the NLR >3.375 group (108.95 weeks, 95%CI: 90.38 ~ 127.51) (P = 0.005). The OS of PLR≤274.63 group (160.40 weeks, 95%CI: 138.41 ~ 182.38) was longer than that of PLR >274.63 group (43.85 weeks, 95%CI: 34.08 ~ 53.63) (P < 0.001). The OS of SII≤399.73 group (176.62 weeks, 95%CI:147.26 ~ 205.97) was longer than that of SII>399.73 group (126.55 weeks,95%CI: 105.04 ~ 148.05) (P = 0.012). The OS was longer in the MHR≤0.58 group (156.24 weeks, 95% CI: 127.05-185.43) than in the MHR>0.58 group (108.11 weeks, 95%CI:86.85-129.38) (P = 0.011). Univariate and multivariate Cox analysis showed that tumor metastasis and PLR>274.63 were independent predictors of the lower OS in elderly patients with TAVTE (P < 0.001). According to the tumor metastasis and the cut-off value of PLR, a combined scoring system MPS (Metastasis and PLR System) was designed. The OS of the 0, 1 and 2 score groups was 184.08 weeks (95%CI:158.11-210.05), 82.60 weeks (95%CI:61.57-103.64), and 23.83 weeks (95%CI: 9.575-38.09) (P < 0.001), respectively.</p><p><strong>Conclusion: </strong>Our findings suggest that the systemic inflammatory markers (NLR, PLR, SII, MHR) may have predictive value for all-cause mortality in elderly patients with TAVTE. PLR combined with tumor metastasis may be an effective index to predict the prognosis of eld
背景:老年肿瘤患者比非肿瘤患者更容易发生静脉血栓事件。探讨老年肿瘤相关性静脉血栓栓塞(TAVTE)患者全身炎症标志物与总生存期(OS)的关系。并探讨淋巴细胞-血小板-淋巴细胞联合比值(PLR)对老年患者肿瘤转移的预后价值。方法:采用前瞻性研究。2017年1月至2019年12月入院的老年TAVTE患者共172例纳入研究,随访2年。收集临床和实验室资料。出院后全因死亡率随访。根据受试者工作特征(ROC)曲线及ROC曲线下面积(AUC)确定中性淋巴细胞比(NLR)、PLR、全身免疫炎症指数(SII)、单核细胞/高密度脂蛋白比(MHR)预测疗效和预后的最佳截止值。Kaplan-meier曲线分析存活时间。采用单因素和多因素COX logistic回归分析老年TAVTE患者OS的独立预测因素。结果:NLR、PLR、SII和MHR的临界值分别为3.375、274.63、399.73和0.58。曲线下面积(AUC)分别为0.639(95%CI: 0.556 ~ 0.721)、0.628(95%CI:0.544 ~ 0.712)、0.595(95%CI:0.510 ~ 0.680)、0.596(95%CI: 0.510 ~ 0.683)。生存分析显示,NLR≤3.375组的OS(181.07周,95%CI: 150.11 ~ 212.03)长于NLR≤3.375组(108.95周,95%CI: 90.38 ~ 127.51) (P = 0.005)。PLR≤274.63组(160.40周,95%CI: 138.41 ~ 182.38)的OS长于PLR≤274.63组(43.85周,95%CI: 34.08 ~ 53.63) (P < 0.001)。SII≤399.73组(176.62周,95%CI: 147.26 ~ 205.97)的OS长于SII≤399.73组(126.55周,95%CI: 105.04 ~ 148.05) (P = 0.012)。MHR≤0.58组的OS(156.24周,95%CI: 127.05-185.43)长于MHR≤0.58组(108.11周,95%CI:86.85-129.38) (P = 0.011)。单因素和多因素Cox分析显示,肿瘤转移和PLR bb0 274.63是老年TAVTE患者较低OS的独立预测因素(P < 0.001)。根据肿瘤转移和PLR的截止值,设计了联合评分系统MPS (metastasis and PLR system)。0、1、2评分组的OS分别为184.08周(95%CI:158.11 ~ 210.05)、82.60周(95%CI:61.57 ~ 103.64)、23.83周(95%CI: 9.575 ~ 38.09) (P < 0.001)。结论:我们的研究结果表明,全身炎症标志物(NLR、PLR、SII、MHR)可能对老年TAVTE患者的全因死亡率具有预测价值。PLR联合肿瘤转移可能是预测老年TAVTE患者预后的有效指标。
{"title":"Prognostic Value of Systemic Inflammatory Markers in Elderly Patients with Tumor-associated Venous Thromboembolism.","authors":"Na Guo, Xinxin Yan, Zhong Yi, Shuihua Yu, Helu Xiu, Yunlei Gao, Songwei Ru, Zuojuan Gong","doi":"10.4103/ijc.ijc_318_23","DOIUrl":"https://doi.org/10.4103/ijc.ijc_318_23","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Elderly tumor patients are more prone to venous thrombotic events than nontumor patients. To investigate the relationship between systemic inflammatory markers and overall survival (OS) in elderly patients with tumorassociated venous thromboembolism (TAVTE). And to evaluate the prognostic value of combined lymphocyte platelettolymphocyte ratio (PLR) with neoplasm metastasis in elderly patients.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A prospective study was conducted. A total of 172 elderly patients with TAVTE admitted to the hospital from January 2017 to December 2019 were included in the study, which were followed up for 2 years. Clinical and laboratory data were collected. All-cause mortality within after discharge were followed up. The optimal cutoff values of neutrophiltolymphocyte ratio (NLR), PLR, systemic immuneinflammation index (SII), and monocyte to highdensity lipoprotein ratio (MHR) for predicting efficacy and prognosis were determined according to receiver operating characteristic (ROC) curve and the areas under the ROC curve (AUC). Kaplan-meier curves were used to analyze the survival time. Univariate and multivariate COX logistic regression analyses were used to analyze the independent predictors of OS in elderly patients with TAVTE.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The cut-off values for NLR, PLR, SII, and MHR were 3.375, 274.63, 399.73 and 0.58, respectively. And the area under the curve (AUC) was 0.639(95%CI: 0.556-0.721), 0.628(95%CI:0.544-0.712), 0.595(95%CI:0.510-0.680) and 0.596(95%CI: 0.510-0.683). Survival analysis showed that OS was longer in the NLR≤3.375 group (181.07 weeks, 95% CI: 150.11 ~ 212.03) than in the NLR &gt;3.375 group (108.95 weeks, 95%CI: 90.38 ~ 127.51) (P = 0.005). The OS of PLR≤274.63 group (160.40 weeks, 95%CI: 138.41 ~ 182.38) was longer than that of PLR &gt;274.63 group (43.85 weeks, 95%CI: 34.08 ~ 53.63) (P &lt; 0.001). The OS of SII≤399.73 group (176.62 weeks, 95%CI:147.26 ~ 205.97) was longer than that of SII&gt;399.73 group (126.55 weeks,95%CI: 105.04 ~ 148.05) (P = 0.012). The OS was longer in the MHR≤0.58 group (156.24 weeks, 95% CI: 127.05-185.43) than in the MHR&gt;0.58 group (108.11 weeks, 95%CI:86.85-129.38) (P = 0.011). Univariate and multivariate Cox analysis showed that tumor metastasis and PLR&gt;274.63 were independent predictors of the lower OS in elderly patients with TAVTE (P &lt; 0.001). According to the tumor metastasis and the cut-off value of PLR, a combined scoring system MPS (Metastasis and PLR System) was designed. The OS of the 0, 1 and 2 score groups was 184.08 weeks (95%CI:158.11-210.05), 82.60 weeks (95%CI:61.57-103.64), and 23.83 weeks (95%CI: 9.575-38.09) (P &lt; 0.001), respectively.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Our findings suggest that the systemic inflammatory markers (NLR, PLR, SII, MHR) may have predictive value for all-cause mortality in elderly patients with TAVTE. PLR combined with tumor metastasis may be an effective index to predict the prognosis of eld","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Second primary cancers: Incidence and outcomes from a population of patients accrued in six prospective controlled trials at a tertiary cancer institute. 第二原发性癌症:从一家三级癌症研究所的六项前瞻性对照试验中得出的患者发病率和结果。
IF 0.9 4区 医学 Q4 ONCOLOGY Pub Date : 2024-12-17 DOI: 10.4103/ijc.IJC_154_20
Abhishek Chatterjee, Sarbani G Laskar, Jayshree Deshmukh, Tejpal Gupta, Vedang Murthy, Jai Prakash Agarwal, Ashwini Budrukkar

Background: The aim of this study was to document the incidence, spectrum and outcomes of Second Primary Malignancy (SPM) in a prospectively followed-up population of Head and Neck Squamous carcinoma (HNSCC) patients accrued in six prospective trials and treated with definitive radiotherapy.

Materials and methods: Patients were prospectively followed up over time and data on SPM collected after IRB approval after establishing the diagnosis of SPM based on clinical criteria. Descriptive statistics to determine clinic demographic characteristics and spectrum of SPM encountered, time to event outcomes (SPM-DFS - Disease-free survival after diagnosis of second primary, SPM-OS - Overall survival after diagnosis of second primary) and univariate analysis of factors of likely prognostic significance were performed.

Results: A total of 656 individual patient records were examined. A total of 43 SPM s were detected at a median follow-up of 62 months (IQR -39-97 months), accounting for a cumulative incidence of 6.5%. The median time to development of an SPM was 48 months. The head and neck (41.84%) and the esophagus (34.8)% were the most common sites of SPM. At a median follow-up of 7 months post-diagnosis of SPM, the 1 year estimates of SPM-DFS and SPM-OS were 37.6% and 40% respectively. Radical intent treatment emerged as a significant predictor of improved SPM-OS and SPM-DFS.

Conclusion: SPMs are a major cause of morbidity and mortality in HNSCC survivors. Timely detection allows for more cases to be treated with radical intent to offer chances for long term control and survival.

背景:本研究的目的是记录六项前瞻性试验中头颈部鳞状癌(HNSCC)患者的前瞻性随访人群中第二原发恶性肿瘤(SPM)的发病率、谱和结局,并接受明确的放射治疗。材料与方法:根据临床标准确定SPM诊断后,经IRB批准后,对患者进行长期前瞻性随访,收集SPM数据。描述性统计以确定临床人口学特征和所遇到的SPM的频谱,到事件结果的时间(SPM- dfs -第二原发诊断后的无病生存期,SPM- os -第二原发诊断后的总生存期)和可能具有预后意义的因素的单变量分析。结果:共检查个人病历656份。中位随访62个月(IQR -39-97个月)共检出43例SPM,累计发病率为6.5%。SPM发展的中位时间为48个月。头颈部(41.84%)和食道(34.8%)是SPM最常见的部位。在SPM诊断后7个月的中位随访中,SPM- dfs和SPM- os的1年估计分别为37.6%和40%。根治性治疗是改善SPM-OS和SPM-DFS的重要预测因子。结论:SPMs是HNSCC幸存者发病和死亡的主要原因。及时发现可使更多病例得到彻底治疗,为长期控制和生存提供机会。
{"title":"Second primary cancers: Incidence and outcomes from a population of patients accrued in six prospective controlled trials at a tertiary cancer institute.","authors":"Abhishek Chatterjee, Sarbani G Laskar, Jayshree Deshmukh, Tejpal Gupta, Vedang Murthy, Jai Prakash Agarwal, Ashwini Budrukkar","doi":"10.4103/ijc.IJC_154_20","DOIUrl":"https://doi.org/10.4103/ijc.IJC_154_20","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to document the incidence, spectrum and outcomes of Second Primary Malignancy (SPM) in a prospectively followed-up population of Head and Neck Squamous carcinoma (HNSCC) patients accrued in six prospective trials and treated with definitive radiotherapy.</p><p><strong>Materials and methods: </strong>Patients were prospectively followed up over time and data on SPM collected after IRB approval after establishing the diagnosis of SPM based on clinical criteria. Descriptive statistics to determine clinic demographic characteristics and spectrum of SPM encountered, time to event outcomes (SPM-DFS - Disease-free survival after diagnosis of second primary, SPM-OS - Overall survival after diagnosis of second primary) and univariate analysis of factors of likely prognostic significance were performed.</p><p><strong>Results: </strong>A total of 656 individual patient records were examined. A total of 43 SPM s were detected at a median follow-up of 62 months (IQR -39-97 months), accounting for a cumulative incidence of 6.5%. The median time to development of an SPM was 48 months. The head and neck (41.84%) and the esophagus (34.8)% were the most common sites of SPM. At a median follow-up of 7 months post-diagnosis of SPM, the 1 year estimates of SPM-DFS and SPM-OS were 37.6% and 40% respectively. Radical intent treatment emerged as a significant predictor of improved SPM-OS and SPM-DFS.</p><p><strong>Conclusion: </strong>SPMs are a major cause of morbidity and mortality in HNSCC survivors. Timely detection allows for more cases to be treated with radical intent to offer chances for long term control and survival.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142835221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of nutritional status on treatment-related toxicities in children with embryonal brain tumors: The need for proactive nutritional management. 营养状况对胚胎性脑肿瘤儿童治疗相关毒性的影响:需要积极的营养管理。
IF 0.9 4区 医学 Q4 ONCOLOGY Pub Date : 2024-12-12 DOI: 10.4103/ijc.IJC_134_21
Maya Prasad, Ekta C Chheda, Tushar Vora, Tejpal Gupta, Girish Chinnaswamy

Background: Children on treatment for brain tumor are at high risk of malnutrition and have significant treatment-related toxicities. However, the impact of nutritional status on outcome and toxicity is not well understood.

Aim: The objective of this study of children with embryonal brain tumor treated at our center was to understand the impact of nutritional status on treatment-related toxicities.

Materials and methods: We undertook this retrospective audit using a risk-stratified protocol between January 2017 and December 2018. Undernutrition was defined as severe or moderate malnutrition as per the World Health Organization (WHO) criteria. Nutritional status was assessed, and treatment-related toxicity (TRT) and survival rates were analyzed in relation to nutritional status at diagnosis and follow-up.

Statistical analysis used: IBM SPSS for Windows, Version 24.0.

Results: In the cohort of 72 patients with embryonal brain tumors, 64% were undernourished (UN) at the start of chemotherapy, and 2.7% were overweight. At the end of chemotherapy, 61% were UN. During the course of chemotherapy, weight gain was documented in 25% and weight loss in 23.8%. Although chemotherapy toxicity and infection were higher in UN children with medulloblastoma, this was not statistically significant. Both overweight children experienced TRT; one relapsed and subsequently died. Nutritional status did not affect survival rates.

Conclusions: Children with embryonal brain tumor are at high nutritional risk, and undernutrition may worsen treatment-related toxicities. Proactive nutritional monitoring and intervention are needed in settings with a high prevalence of malnutrition and infections.

背景:接受脑肿瘤治疗的儿童营养不良的风险很高,并且具有显著的治疗相关毒性。然而,营养状况对结果和毒性的影响尚不清楚。目的:本研究的目的是了解营养状况对治疗相关毒性的影响。材料和方法:我们在2017年1月至2018年12月期间使用风险分层方案进行了回顾性审核。根据世界卫生组织(卫生组织)的标准,营养不良被定义为严重或中度营养不良。评估营养状况,分析治疗相关毒性(TRT)和生存率与诊断和随访时营养状况的关系。统计分析使用:IBM SPSS for Windows, Version 24.0。结果:在72例胚胎性脑肿瘤患者队列中,化疗开始时营养不良(UN)占64%,超重2.7%。化疗结束时,61%为UN。在化疗过程中,体重增加的占25%,体重减轻的占23.8%。虽然联合国儿童髓母细胞瘤的化疗毒性和感染较高,但这没有统计学意义。两名超重儿童都经历了TRT;1例复发,随后死亡。营养状况不影响存活率。结论:胚胎性脑肿瘤患儿营养风险高,营养不良可能加重治疗相关的毒性。在营养不良和感染高发的环境中,需要进行主动营养监测和干预。
{"title":"The impact of nutritional status on treatment-related toxicities in children with embryonal brain tumors: The need for proactive nutritional management.","authors":"Maya Prasad, Ekta C Chheda, Tushar Vora, Tejpal Gupta, Girish Chinnaswamy","doi":"10.4103/ijc.IJC_134_21","DOIUrl":"https://doi.org/10.4103/ijc.IJC_134_21","url":null,"abstract":"<p><strong>Background: </strong>Children on treatment for brain tumor are at high risk of malnutrition and have significant treatment-related toxicities. However, the impact of nutritional status on outcome and toxicity is not well understood.</p><p><strong>Aim: </strong>The objective of this study of children with embryonal brain tumor treated at our center was to understand the impact of nutritional status on treatment-related toxicities.</p><p><strong>Materials and methods: </strong>We undertook this retrospective audit using a risk-stratified protocol between January 2017 and December 2018. Undernutrition was defined as severe or moderate malnutrition as per the World Health Organization (WHO) criteria. Nutritional status was assessed, and treatment-related toxicity (TRT) and survival rates were analyzed in relation to nutritional status at diagnosis and follow-up.</p><p><strong>Statistical analysis used: </strong>IBM SPSS for Windows, Version 24.0.</p><p><strong>Results: </strong>In the cohort of 72 patients with embryonal brain tumors, 64% were undernourished (UN) at the start of chemotherapy, and 2.7% were overweight. At the end of chemotherapy, 61% were UN. During the course of chemotherapy, weight gain was documented in 25% and weight loss in 23.8%. Although chemotherapy toxicity and infection were higher in UN children with medulloblastoma, this was not statistically significant. Both overweight children experienced TRT; one relapsed and subsequently died. Nutritional status did not affect survival rates.</p><p><strong>Conclusions: </strong>Children with embryonal brain tumor are at high nutritional risk, and undernutrition may worsen treatment-related toxicities. Proactive nutritional monitoring and intervention are needed in settings with a high prevalence of malnutrition and infections.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of anthracycline-induced cardiotoxicity using cardiac biomarkers: A prospective study. 使用心脏生物标志物评估蒽环类药物引起的心脏毒性:一项前瞻性研究。
IF 0.9 4区 医学 Q4 ONCOLOGY Pub Date : 2024-12-12 DOI: 10.4103/ijc.IJC_818_20
Krishna Prasad, Budhi Singh Yadav, Deepy Zohmangaihi, Nagarjun Ballari, Saurabh Mehrotra

Background: Though anthracyclines are the commonly used chemotherapeutics for cancer treatment, close monitoring of patients is required due to its well reported cardiotoxicity. The present study evaluates the role of biomarkers [N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high sensitivity cardiac troponin-T (hs-cTnT)] in early prediction of cardiotoxicity in patients with breast and ovarian cancer who received anthracyclines.

Methods: This was a single-center observational study conducted between August-2018 and January-2020. Doxorubicin was used as an anthracycline at a dose of 50 mg/m2 per cycle. All the patients underwent echocardiography before the start and at 3 months, 6 months and 12 months after chemotherapy. NT-proBNP and hs-cTnT levels were measured before as baseline and within 24 hours of the first and last cycle of anthracycline-based chemotherapy.

Results: A total of 72 patients with breast and ovarian cancer participated in the study. The mean age of patients was 49.4 ± 10.3 years. Sixty six (91.7%) patients had breast cancer and 9 (12.5%) patients developed cardiotoxicity. Mean age of the patients who developed cardiotoxicity was 55.00 ± 12.5 years. The level of NT-proBNP and hs-cTnT were significantly increased after the last cycle of anthracycline in patients who developed cardiotoxicity.

Conclusion: The measurement of NT-proBNP and hs-cTnT levels after anthracycline administration helps detect early sub-clinical cardiotoxicity and thus can assist in modification of therapeutic regimens and initiation of heart failure therapy to prevent future cardiac events.

背景:尽管蒽环类药物是癌症治疗常用的化疗药物,但由于其心脏毒性已被广泛报道,因此需要对患者进行密切监测。本研究评估了生物标志物[n端前b型利钠肽(NT-proBNP)和高敏感性心肌肌钙蛋白-t (hs-cTnT)]在早期预测接受蒽环类药物治疗的乳腺癌和卵巢癌患者心脏毒性中的作用。方法:这是一项单中心观察性研究,于2018年8月至2020年1月进行。阿霉素作为蒽环类药物使用,剂量为50mg /m2 /周期。所有患者在化疗开始前、化疗后3个月、6个月和12个月均行超声心动图检查。NT-proBNP和hs-cTnT水平在蒽环类药物化疗的第一个和最后一个周期之前和24小时内作为基线进行测量。结果:共有72例乳腺癌和卵巢癌患者参与了研究。患者平均年龄49.4±10.3岁。66例(91.7%)患者发生乳腺癌,9例(12.5%)患者发生心脏毒性。发生心脏毒性的患者平均年龄为55.00±12.5岁。发生心脏毒性的患者在最后一个蒽环类药物周期后NT-proBNP和hs-cTnT水平显著升高。结论:蒽环类药物给药后检测NT-proBNP和hs-cTnT水平有助于发现早期亚临床心脏毒性,从而有助于修改治疗方案和开始心力衰竭治疗,以预防未来的心脏事件。
{"title":"Evaluation of anthracycline-induced cardiotoxicity using cardiac biomarkers: A prospective study.","authors":"Krishna Prasad, Budhi Singh Yadav, Deepy Zohmangaihi, Nagarjun Ballari, Saurabh Mehrotra","doi":"10.4103/ijc.IJC_818_20","DOIUrl":"https://doi.org/10.4103/ijc.IJC_818_20","url":null,"abstract":"<p><strong>Background: </strong>Though anthracyclines are the commonly used chemotherapeutics for cancer treatment, close monitoring of patients is required due to its well reported cardiotoxicity. The present study evaluates the role of biomarkers [N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high sensitivity cardiac troponin-T (hs-cTnT)] in early prediction of cardiotoxicity in patients with breast and ovarian cancer who received anthracyclines.</p><p><strong>Methods: </strong>This was a single-center observational study conducted between August-2018 and January-2020. Doxorubicin was used as an anthracycline at a dose of 50 mg/m2 per cycle. All the patients underwent echocardiography before the start and at 3 months, 6 months and 12 months after chemotherapy. NT-proBNP and hs-cTnT levels were measured before as baseline and within 24 hours of the first and last cycle of anthracycline-based chemotherapy.</p><p><strong>Results: </strong>A total of 72 patients with breast and ovarian cancer participated in the study. The mean age of patients was 49.4 ± 10.3 years. Sixty six (91.7%) patients had breast cancer and 9 (12.5%) patients developed cardiotoxicity. Mean age of the patients who developed cardiotoxicity was 55.00 ± 12.5 years. The level of NT-proBNP and hs-cTnT were significantly increased after the last cycle of anthracycline in patients who developed cardiotoxicity.</p><p><strong>Conclusion: </strong>The measurement of NT-proBNP and hs-cTnT levels after anthracycline administration helps detect early sub-clinical cardiotoxicity and thus can assist in modification of therapeutic regimens and initiation of heart failure therapy to prevent future cardiac events.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recurrence patterns-analysis from a South Indian breast cancer patient cohort. 复发模式-来自南印度乳腺癌患者队列的分析。
IF 0.9 4区 医学 Q4 ONCOLOGY Pub Date : 2024-12-12 DOI: 10.4103/ijc.IJC_561_20
Jayanti Thumsi, Aparna Gunda, Mallika Natraj, Manjiri M Bakre

Background: The current study analyzes the pattern of recurrence/relapse in breast cancer patients belonging to different receptor subtypes to help enhance therapeutic and surveillance methods.

Methods: This is an observational prospective study of a cohort of 543 patients from South India. Associations between various factors and their significance in relapse were assessed by odds ratio (OR), Chi-square test, and two-sided P value.

Results: Relapse of cancer in all receptor subtypes was significantly associated with stage III (P = 0.0029). Of the 48 patients who had a relapse of cancer, 42% had relapsed at a distance recurrence (DR), 23% (P = 0.02) had loco/locoregional recurrence (LLR) and the rest had relapsed at distant and loco/locoregional sites. HER2+ (human epidermal growth factor receptor) (83%) and hormone receptor (HR+/HER2-) (77%) patients had higher DR rates with an OR of 2 (95% Confidence Interval, 0.6-6) and 0.47 (95% CI, 0.1-2.1), respectively compared to TNBC (triple-negative breast cancer) patients. TNBCs (80%) had higher LLR rates over HER2+ (50%) and HR+/HER2- (44%) with an OR of 2 (95% CI, 0.6-6) and 2.1 (95% CI, 0.47-9.3), respectively. Bones and lungs in HR+/HER2- patients, liver and lungs for HER2 + patients, and bones in TNBC patients were the preferred sites for metastasis. The number of metastatic sites followed the order, TNBCs > HER2+>HR+/HER2-.

Conclusions: HR+/HER2- and HER+ patients were more associated with DRs and TNBC patients were associated with LLR. TNBC patients recurred at multiple sites compared to the other two subtypes. Overall, there seems to be a trend in the recurrence across receptor subtypes. Understanding this recurrence pattern will help in enhancing therapeutic and surveillance methods.

背景:本研究旨在分析不同受体亚型乳腺癌患者的复发/复发模式,以帮助改进治疗和监测方法。方法:这是一项来自南印度的543例患者的观察性前瞻性研究。采用比值比(OR)、卡方检验和双侧P值评价各因素与复发的相关性及其显著性。结果:所有受体亚型的癌症复发与III期有显著相关性(P = 0.0029)。在48例癌症复发患者中,42%为远处复发(DR), 23% (P = 0.02)为局部/局部复发(LLR),其余为远处和局部/局部复发(P = 0.02)。与TNBC(三阴性乳腺癌)患者相比,HER2+(人表皮生长因子受体)(83%)和激素受体(HR+/HER2-)(77%)患者的DR率更高,OR分别为2(95%置信区间,0.6-6)和0.47 (95% CI, 0.1-2.1)。tnbc(80%)的LLR率高于HER2+(50%)和HR+/HER2- (44%), OR分别为2 (95% CI, 0.6-6)和2.1 (95% CI, 0.47-9.3)。HR+/HER2-患者的骨和肺、HER2 +患者的肝和肺以及TNBC患者的骨是转移的首选部位。转移部位的数量依次为tnbc > HER2+>HR+/HER2-。结论:HR+/HER2-和HER+患者与dr的相关性更高,TNBC患者与LLR的相关性更高。与其他两种亚型相比,TNBC患者在多个部位复发。总的来说,似乎有一种跨受体亚型复发的趋势。了解这种复发模式将有助于加强治疗和监测方法。
{"title":"Recurrence patterns-analysis from a South Indian breast cancer patient cohort.","authors":"Jayanti Thumsi, Aparna Gunda, Mallika Natraj, Manjiri M Bakre","doi":"10.4103/ijc.IJC_561_20","DOIUrl":"https://doi.org/10.4103/ijc.IJC_561_20","url":null,"abstract":"<p><strong>Background: </strong>The current study analyzes the pattern of recurrence/relapse in breast cancer patients belonging to different receptor subtypes to help enhance therapeutic and surveillance methods.</p><p><strong>Methods: </strong>This is an observational prospective study of a cohort of 543 patients from South India. Associations between various factors and their significance in relapse were assessed by odds ratio (OR), Chi-square test, and two-sided P value.</p><p><strong>Results: </strong>Relapse of cancer in all receptor subtypes was significantly associated with stage III (P = 0.0029). Of the 48 patients who had a relapse of cancer, 42% had relapsed at a distance recurrence (DR), 23% (P = 0.02) had loco/locoregional recurrence (LLR) and the rest had relapsed at distant and loco/locoregional sites. HER2+ (human epidermal growth factor receptor) (83%) and hormone receptor (HR+/HER2-) (77%) patients had higher DR rates with an OR of 2 (95% Confidence Interval, 0.6-6) and 0.47 (95% CI, 0.1-2.1), respectively compared to TNBC (triple-negative breast cancer) patients. TNBCs (80%) had higher LLR rates over HER2+ (50%) and HR+/HER2- (44%) with an OR of 2 (95% CI, 0.6-6) and 2.1 (95% CI, 0.47-9.3), respectively. Bones and lungs in HR+/HER2- patients, liver and lungs for HER2 + patients, and bones in TNBC patients were the preferred sites for metastasis. The number of metastatic sites followed the order, TNBCs > HER2+>HR+/HER2-.</p><p><strong>Conclusions: </strong>HR+/HER2- and HER+ patients were more associated with DRs and TNBC patients were associated with LLR. TNBC patients recurred at multiple sites compared to the other two subtypes. Overall, there seems to be a trend in the recurrence across receptor subtypes. Understanding this recurrence pattern will help in enhancing therapeutic and surveillance methods.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Carcinoma colon masquerading as bleeding per vagina. 伪装成阴道出血的结肠癌。
IF 0.9 4区 医学 Q4 ONCOLOGY Pub Date : 2024-10-30 DOI: 10.4103/ijc.IJC_166_21
Madhu Muralee, M Srinidhi, V M Bharath, C D Sivanandan

Abstract: Isolated vaginal metastasis from colorectal cancer is a rare entity with very few reports in the literature. Here we report a patient who presented with bleeding per vagina from a vaginal mucosal lesion. Biopsy of the vaginal lesion indicated a metastatic adenocarcinoma from a colorectal primary. Further workup of the patient with colonoscopy and Positron emission tomography (PET CT) indicated a primary in the sigmoid colon. As the patient had a single site of metastasis, she was planned for definitive management. The colonic primary, as well as the vaginal deposit were managed surgically. Further, the patient received adjuvant chemotherapy as well as adjuvant external beam radiation to the site of the vaginal lesion. Vaginal metastases from colorectal primary are usually part of systemic dissemination with multiple metastatic sites and hence has poor prognosis. When the patient presents with an isolated metastasis in the vagina., the survival appears reasonable as per the few reports available in the literature. Due to the rarity of the presentation, there are no standard treatment guidelines available. Surgical management, radiation and adjuvant chemotherapy have been used in varying combinations in the reports available in the literature. To conclude, vaginal metastasis should be included in the differential diagnosis of patients presenting with vaginal bleeding, especially with a history of colorectal carcinoma. Available limited evidence suggests that isolated vaginal metastasis from colorectal cancer that is amenable to local surgical resection has a reasonable outcome. Hence, isolated vaginal metastasis should be treated with curative intent in a multidisciplinary context like other sites of oligometastatic disease.

摘要:结直肠癌孤立性阴道转移是一种罕见病症,文献中鲜有报道。本文报告了一名因阴道粘膜病变导致阴道出血的患者。阴道病变活检显示为大肠原发转移性腺癌。通过结肠镜和正电子发射断层扫描(PET CT)对患者进行进一步检查,结果显示原发于乙状结肠。由于患者只有一个转移部位,因此计划对她进行最终治疗。对结肠原发灶和阴道沉积物进行了手术治疗。此外,患者还接受了辅助化疗以及阴道病灶部位的辅助外照射。结直肠原发癌的阴道转移灶通常是全身扩散的一部分,有多个转移部位,因此预后较差。当患者出现阴道孤立转移时,根据现有的少数文献报道,生存率似乎是合理的。由于这种病症的罕见性,目前还没有标准的治疗指南。在现有的文献报道中,手术治疗、放射治疗和辅助化疗以不同的组合方式被使用。总之,阴道转移应列入阴道出血患者的鉴别诊断中,尤其是有结直肠癌病史的患者。现有的有限证据表明,可进行局部手术切除的结直肠癌孤立性阴道转移瘤具有合理的预后。因此,孤立的阴道转移灶应与其他部位的少转移疾病一样,在多学科背景下进行根治性治疗。
{"title":"Carcinoma colon masquerading as bleeding per vagina.","authors":"Madhu Muralee, M Srinidhi, V M Bharath, C D Sivanandan","doi":"10.4103/ijc.IJC_166_21","DOIUrl":"https://doi.org/10.4103/ijc.IJC_166_21","url":null,"abstract":"<p><strong>Abstract: </strong>Isolated vaginal metastasis from colorectal cancer is a rare entity with very few reports in the literature. Here we report a patient who presented with bleeding per vagina from a vaginal mucosal lesion. Biopsy of the vaginal lesion indicated a metastatic adenocarcinoma from a colorectal primary. Further workup of the patient with colonoscopy and Positron emission tomography (PET CT) indicated a primary in the sigmoid colon. As the patient had a single site of metastasis, she was planned for definitive management. The colonic primary, as well as the vaginal deposit were managed surgically. Further, the patient received adjuvant chemotherapy as well as adjuvant external beam radiation to the site of the vaginal lesion. Vaginal metastases from colorectal primary are usually part of systemic dissemination with multiple metastatic sites and hence has poor prognosis. When the patient presents with an isolated metastasis in the vagina., the survival appears reasonable as per the few reports available in the literature. Due to the rarity of the presentation, there are no standard treatment guidelines available. Surgical management, radiation and adjuvant chemotherapy have been used in varying combinations in the reports available in the literature. To conclude, vaginal metastasis should be included in the differential diagnosis of patients presenting with vaginal bleeding, especially with a history of colorectal carcinoma. Available limited evidence suggests that isolated vaginal metastasis from colorectal cancer that is amenable to local surgical resection has a reasonable outcome. Hence, isolated vaginal metastasis should be treated with curative intent in a multidisciplinary context like other sites of oligometastatic disease.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gene of the month: C-KIT. 本月基因C-KIT。
IF 0.9 4区 医学 Q4 ONCOLOGY Pub Date : 2024-10-30 DOI: 10.4103/ijc.ijc_1350_21
Niraj Kumari, Raghavendra Lingaiah

Abstract: KIT is a gene coding for tyrosine kinase receptor, which was identified as the ligand of stem cell factor. Its role in disease was first identified in gastrointestinal stromal tumor. However, later, this gene was found to be implicated in many other benign and malignant tumors. C-KIT has been studied as the first biomarker for targeted therapy. Herein we review its structure, function and role in various non-neoplastic and neoplastic diseases.

摘要:KIT 是酪氨酸激酶受体的编码基因,被确认为干细胞因子的配体。它在疾病中的作用最早是在胃肠道间质瘤中发现的。不过,后来发现该基因与许多其他良性和恶性肿瘤都有关联。C-KIT 已被研究为靶向治疗的首个生物标记物。在此,我们回顾了它的结构、功能以及在各种非肿瘤性和肿瘤性疾病中的作用。
{"title":"Gene of the month: C-KIT.","authors":"Niraj Kumari, Raghavendra Lingaiah","doi":"10.4103/ijc.ijc_1350_21","DOIUrl":"https://doi.org/10.4103/ijc.ijc_1350_21","url":null,"abstract":"<p><strong>Abstract: </strong>KIT is a gene coding for tyrosine kinase receptor, which was identified as the ligand of stem cell factor. Its role in disease was first identified in gastrointestinal stromal tumor. However, later, this gene was found to be implicated in many other benign and malignant tumors. C-KIT has been studied as the first biomarker for targeted therapy. Herein we review its structure, function and role in various non-neoplastic and neoplastic diseases.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary intraosseous malignant peripheral nerve sheath tumor of clavicle: Report of a rare entity.
IF 0.9 4区 医学 Q4 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2025-02-17 DOI: 10.4103/ijc.IJC_170_21
Prateek Hegde, Amit Janu, Bharat Rekhi, Ashish Gulia, Ajay Puri

Abstract: Malignant peripheral nerve sheath tumors (MPNST) are mesenchymal tumors that develop or differentiate from cells of the peripheral nerve sheath. Intraosseous MPNST is extremely uncommon and usually results from secondary invasion. A 17-year-old male presented with pain and swelling over the left collar bone. Imaging revealed an expansile lytic lesion involving the subarticular region of the clavicle with a cortical break and infiltration of the adjacent soft tissues. Biopsy findings were consistent with cellular nerve sheath tumor with significant atypia and mitoses, along with S100 protein immunopositivity indicative of MPNST. The patient was treated with neoadjuvant radiotherapy, followed by wide local excision. To the best of our knowledge, the present case constitutes the first case of a primary intraosseous MPNST involving the clavicle. The case is presented in view of its rarity and with relevant review.

{"title":"Primary intraosseous malignant peripheral nerve sheath tumor of clavicle: Report of a rare entity.","authors":"Prateek Hegde, Amit Janu, Bharat Rekhi, Ashish Gulia, Ajay Puri","doi":"10.4103/ijc.IJC_170_21","DOIUrl":"https://doi.org/10.4103/ijc.IJC_170_21","url":null,"abstract":"<p><strong>Abstract: </strong>Malignant peripheral nerve sheath tumors (MPNST) are mesenchymal tumors that develop or differentiate from cells of the peripheral nerve sheath. Intraosseous MPNST is extremely uncommon and usually results from secondary invasion. A 17-year-old male presented with pain and swelling over the left collar bone. Imaging revealed an expansile lytic lesion involving the subarticular region of the clavicle with a cortical break and infiltration of the adjacent soft tissues. Biopsy findings were consistent with cellular nerve sheath tumor with significant atypia and mitoses, along with S100 protein immunopositivity indicative of MPNST. The patient was treated with neoadjuvant radiotherapy, followed by wide local excision. To the best of our knowledge, the present case constitutes the first case of a primary intraosseous MPNST involving the clavicle. The case is presented in view of its rarity and with relevant review.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"61 4","pages":"823-828"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence of postoperative pulmonary complications and associated risk factors after major oncosurgeries: Prospective observational study.
IF 0.9 4区 医学 Q4 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2025-02-17 DOI: 10.4103/ijc.IJC_266_21
Shilpi Agarwal, Rakesh Garg, Sushma Bhatnagar, Seema Mishra, Sachidanand Jee Bharati, Nishkarsh Gupta, Vinod Kumar

Background: Postoperative pulmonary complications (PPCs) are defined heterogeneously and have major adverse effects in increasing morbidity. Oncosurgeries themselves are complex, are of long duration, and extensive handling of body tissues occurs in them, leading to various complications including PPCs. So, we conducted this prospective study intending to find the incidence and risk factors for PPCs in patients undergoing major oncosurgeries.

Methods: This prospective observational study was conducted after obtaining institutional ethical approval in patients undergoing major oncosurgeries. The demographic, preoperative, and intraoperative details were noted, and patients were followed in the postoperative period for the occurrence of PPC till discharge. Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) score was used to predict the occurrence of PPC. Data were analyzed using multivariable regression analysis for the risk factors, and the Chi-square trend was used to see the trend of PPC with the change in ARISCAT score.

Results: The overall incidence of PPC in patients undergoing major oncosurgeries was 28.05%. The most common PPCs were respiratory insufficiency (19.2%) and atelectasis (17.6%). The highest incidence of PPC was found in thoracotomies (41.6%), followed by cytoreductive surgeries (40.6%). The risk factors for PPCs included body mass index (BMI) <18.5 or >25 kg/m2, smoking, use of nasogastric tube, age >60 years, and albumin <3.5 g/dL. Patients with low ARISCAT scores had a low incidence of PPC compared to those with high and intermediate ARISCAT scores.

Conclusion: The incidence of PPC in patients undergoing major oncosurgeries was 28.05% in our study. The independent risk factors for PPC in oncological surgeries were BMI <18.5 kg/m2 or >25 kg/m2, use of nasogastric tube, age <60 years, serum albumin <3.5 g/dL, and smoking.

{"title":"Incidence of postoperative pulmonary complications and associated risk factors after major oncosurgeries: Prospective observational study.","authors":"Shilpi Agarwal, Rakesh Garg, Sushma Bhatnagar, Seema Mishra, Sachidanand Jee Bharati, Nishkarsh Gupta, Vinod Kumar","doi":"10.4103/ijc.IJC_266_21","DOIUrl":"https://doi.org/10.4103/ijc.IJC_266_21","url":null,"abstract":"<p><strong>Background: </strong>Postoperative pulmonary complications (PPCs) are defined heterogeneously and have major adverse effects in increasing morbidity. Oncosurgeries themselves are complex, are of long duration, and extensive handling of body tissues occurs in them, leading to various complications including PPCs. So, we conducted this prospective study intending to find the incidence and risk factors for PPCs in patients undergoing major oncosurgeries.</p><p><strong>Methods: </strong>This prospective observational study was conducted after obtaining institutional ethical approval in patients undergoing major oncosurgeries. The demographic, preoperative, and intraoperative details were noted, and patients were followed in the postoperative period for the occurrence of PPC till discharge. Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) score was used to predict the occurrence of PPC. Data were analyzed using multivariable regression analysis for the risk factors, and the Chi-square trend was used to see the trend of PPC with the change in ARISCAT score.</p><p><strong>Results: </strong>The overall incidence of PPC in patients undergoing major oncosurgeries was 28.05%. The most common PPCs were respiratory insufficiency (19.2%) and atelectasis (17.6%). The highest incidence of PPC was found in thoracotomies (41.6%), followed by cytoreductive surgeries (40.6%). The risk factors for PPCs included body mass index (BMI) <18.5 or >25 kg/m2, smoking, use of nasogastric tube, age >60 years, and albumin <3.5 g/dL. Patients with low ARISCAT scores had a low incidence of PPC compared to those with high and intermediate ARISCAT scores.</p><p><strong>Conclusion: </strong>The incidence of PPC in patients undergoing major oncosurgeries was 28.05% in our study. The independent risk factors for PPC in oncological surgeries were BMI <18.5 kg/m2 or >25 kg/m2, use of nasogastric tube, age <60 years, serum albumin <3.5 g/dL, and smoking.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"61 4","pages":"766-774"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship between surgical compliance and survival outcome in patients with Ewing sarcoma.
IF 0.9 4区 医学 Q4 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2025-02-17 DOI: 10.4103/ijc.IJC_138_21
Bin Chen, Hong-Zhuo Li, Xiao-Feng He

Background: The impact of surgical compliance on survival outcomes in patients with Ewing sarcoma (ES) is unclear, so this study was performed to explore the association between them.

Methods: We used the SEER*Stat software (version 8.3.6.1) to extract information on ES patients from the SEER database. Patients were divided into two groups based on their adherence to surgical recommendations: the surgical compliance group and the surgical noncompliance group. Categorical variables were expressed as percentages. Multivariate logistic regression and Chi-square test were used to explore variables related to surgical compliance. Univariate Cox regression analysis was used to initially select potential prognostic factors, and then the factors selected in the univariate Cox regression analysis were further analyzed in a multivariate Cox proportional risk model to ultimately determine the risk prognostic factors significantly related to the survival of patients with ES.

Results: Multiple logistic regression analysis suggested that adults (OR = 0.373, 95% confidence interval (CI): 0.164-0.849), Grade IV (OR = 0.373, 95% CI: 0.164-0.849), and unmarried patients (OR = 0.568, 95% CI: 0.339-0.954) were more inclined to accept surgery recommendations, while patients from 2001 to 2010 were less compliant with surgery. Multifactorial Cox regression analysis suggested that surgical compliance was an independent prognostic factor for patients with ES. Through the Kaplan-Meier survival curves, we could clearly observe that the overall survival was higher in the surgical compliance group than in the surgical noncompliance group. Furthermore, subgroup analysis also reached similar conclusions.

Conclusion: In this study, we found that surgical compliance was an independent predictor of patient prognosis. Furthermore, we found that age, tumor grade, year of diagnosis, and marital status may be related to surgical compliance.

{"title":"Relationship between surgical compliance and survival outcome in patients with Ewing sarcoma.","authors":"Bin Chen, Hong-Zhuo Li, Xiao-Feng He","doi":"10.4103/ijc.IJC_138_21","DOIUrl":"https://doi.org/10.4103/ijc.IJC_138_21","url":null,"abstract":"<p><strong>Background: </strong>The impact of surgical compliance on survival outcomes in patients with Ewing sarcoma (ES) is unclear, so this study was performed to explore the association between them.</p><p><strong>Methods: </strong>We used the SEER*Stat software (version 8.3.6.1) to extract information on ES patients from the SEER database. Patients were divided into two groups based on their adherence to surgical recommendations: the surgical compliance group and the surgical noncompliance group. Categorical variables were expressed as percentages. Multivariate logistic regression and Chi-square test were used to explore variables related to surgical compliance. Univariate Cox regression analysis was used to initially select potential prognostic factors, and then the factors selected in the univariate Cox regression analysis were further analyzed in a multivariate Cox proportional risk model to ultimately determine the risk prognostic factors significantly related to the survival of patients with ES.</p><p><strong>Results: </strong>Multiple logistic regression analysis suggested that adults (OR = 0.373, 95% confidence interval (CI): 0.164-0.849), Grade IV (OR = 0.373, 95% CI: 0.164-0.849), and unmarried patients (OR = 0.568, 95% CI: 0.339-0.954) were more inclined to accept surgery recommendations, while patients from 2001 to 2010 were less compliant with surgery. Multifactorial Cox regression analysis suggested that surgical compliance was an independent prognostic factor for patients with ES. Through the Kaplan-Meier survival curves, we could clearly observe that the overall survival was higher in the surgical compliance group than in the surgical noncompliance group. Furthermore, subgroup analysis also reached similar conclusions.</p><p><strong>Conclusion: </strong>In this study, we found that surgical compliance was an independent predictor of patient prognosis. Furthermore, we found that age, tumor grade, year of diagnosis, and marital status may be related to surgical compliance.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"61 4","pages":"749-758"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Indian journal of cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1